Glucotrack submits IDE to FDA for US clinical study of implantable CBGM

Glucotrack, Inc.

Glucotrack submitted an IDE application to the FDA to initiate a US clinical study of its fully implantable continuous blood glucose monitoring (CBGM) system.
CBGM is designed for 3-year sensor longevity, blood-based accuracy, and no on-body wearable component.
Company plans to proceed with US clinical study following FDA review and approval of the IDE.
IDE submission follows years of preclinical evaluation and iterative engineering; data support advancing to clinical evaluation.
CEO Paul Goode stated the submission reflects progress toward offering a discreet, accurate CGM option for diabetes patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.